JCJulijana Conic

Julijana Conic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julijana Conic has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Chetty

    Section of General Internal Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA

    1 shared publication
  • Alexei Y. Bagrov

    Padakonn Pharma, 20309 Narva, Estonia

    1 shared publication
  • Audrey Marsh

    Section of General Internal Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA

    1 shared publication
  • B. Boulmay

    Louisiana State University Health Sciences Center- Department of Internal Medicine, Section of Hematology/Oncology, New Orleans, LA, USA

    1 shared publication
  • Brendan Agatisa-Boyle

    Department of Cellular and Molecular Medicine, Lerner Research Institute Cleveland Clinic, Cleveland, OH 44106, USA

    1 shared publication
  • Brendan Sheehy

    Department of Cellular and Molecular Medicine, Lerner Research Institute Cleveland Clinic, Cleveland, OH 44106, USA

    1 shared publication

Latest Publications

  • Open Access

    Effect of Steroids on the Progression of Alzheimer's Dementia: A Retrospective Chart Review

    by Julijana Zoran Conic, Alexandra Chetty, Lily Chen, Audrey Marsh, Sean Barry, Rodney Pattabhi, Thomas Reske, Erwin Aguilar, Lobna Ali

    Objectives: Alzheimer's disease (AD) is a prevalent age‐related neurodegenerative disease that affects millions of individuals in the United States. Neuroinflammation is a driver of the neurodegenerative changes that characterize AD, prompting interest in how inflammation can be modulated for treatment and prevention.Methods: ICD‐10 codes were quarried from electronic medical records to identify patients diagnosed with AD from 2012 to 2020. The patients were then divided into those who used systemic steroids and those who did not before the progression of their disease. Data on medication prescribed was used to measure the disease's progression. Clinical findings and laboratory results were collected to build a propensity score. Patients were followed until disease progression, death, or the last available visit. Kaplan–Meier curves and hazard ratios adjusted for the propensity score were used to compare the two groups.Results: Of the 459 patients identified, 77 were included in the study, and 13 used steroids. Of the 77 patients included in the study, 59 had progression of their disease, and of those, five used steroids. The median time to progression was 408.00 (191.00, 979.00) days for the overall sample. The hazard ratio (HR) comparing the group using steroids to those not using steroids was 0.26 with a 95% CI of (0.1013, 0.673) and a p value of 0.00064.Conclusions: In our study, steroid use delayed the progression of dementia. Further study is needed to outline how steroids and anti‐inflammatory medications can be used in the treatment and prevention of AD.


  • Open Access

    Trends in Medicare utilization and reimbursement for hematology/oncology procedures from 2012 to 2023: A geriatric oncology perspective

    by J. Conic, T. Reske

    Objectives: Given the scarcity of data exploring reimbursement trends in the field of hematology/oncology, we sought to characterize these trends for common procedures in this field from 2012 to 2023.Methods: Using the Centers for Medicare and Medicaid Services' Physician Fee Schedule Look‐Up Tool we collected reimbursement data for 40 hematology/oncology procedure codes from 2012 to 2023. Data was adjusted to 2023 United States (US) dollars using the Consumer Price Index (CPI).Results: From 2012 to 2023 gross reimbursement for the facility price decreased 4.4% and increased 9.2% for the non‐facility price. When adjusted for inflation, compensation decreased 96.1% and 96.6%, respectively. None of the 40 examined Current Procedural Terminology (CPT) codes increased in net reimbursement over the study period.Conclusions: Medicare reimbursement for common hematology/oncology procedures decreased from 2012 to 2023. Further research is necessary to explore the implications of these trends on the delivery of patient care.


  • Open Access

    Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na+/K+-ATPase Profibrotic Signaling Pathways

    by David J. Kennedy, Fatimah K. Khalaf, Brendan Sheehy, Malory E. Weber, Brendan Agatisa-Boyle, Julijana Conic, Kayla Hauser, Charles M. Medert, Kristen Westfall, Philip Bucur, et al.

    Cardiotonic steroids (CTS) are Na+/K+-ATPase (NKA) ligands that are elevated in volume-expanded states and associated with cardiac and renal dysfunction in both clinical and experimental settings. We test the hypothesis that the CTS telocinobufagin (TCB) promotes renal dysfunction in a process involving signaling through the NKA α-1 in the following studies. First, we infuse TCB (4 weeks at 0.1 µg/g/day) or a vehicle into mice expressing wild-type (WT) NKA α-1, as well as mice with a genetic reduction (~40%) of NKA α-1 (NKA α-1+/−). Continuous TCB infusion results in increased proteinuria and cystatin C in WT mice which are significantly attenuated in NKA α-1+/− mice (all p < 0.05), despite similar increases in blood pressure. In a series of in vitro experiments, 24-h treatment of HK2 renal proximal tubular cells with TCB results in significant dose-dependent increases in both Collagens 1 and 3 mRNA (2-fold increases at 10 nM, 5-fold increases at 100 nM, p < 0.05). Similar effects are seen in primary human renal mesangial cells. TCB treatment (100 nM) of SYF fibroblasts reconstituted with cSrc results in a 1.5-fold increase in Collagens 1 and 3 mRNA (p < 0.05), as well as increases in both Transforming Growth factor beta (TGFb, 1.5 fold, p < 0.05) and Connective Tissue Growth Factor (CTGF, 2 fold, p < 0.05), while these effects are absent in SYF cells without Src kinase. In a patient study of subjects with chronic kidney disease, TCB is elevated compared to healthy volunteers. These studies suggest that the pro-fibrotic effects of TCB in the kidney are mediated though the NKA-Src kinase signaling pathway and may have relevance to volume-overloaded conditions, such as chronic kidney disease where TCB is elevated.